内容紹介
Summary
Background: Oral mucositis and body weight loss are the most critical conditions known to lead to the discontinuation of chemoradiotherapy for head and neck cancer. We investigated the effect of a nutritional supplement with a high blend ratio of ω-3 fatty acids(Prosure®)on body weight loss, oral mucositis, and the completion rate of chemoradiotherapy in patients with oropharyngeal and hypopharyngeal cancer. Patients and methods: The study group comprised patients with oropharyngeal and hypopharyngeal cancer who were treated with concomitant cisplatin and 70 Gy of radiotherapy. These patients received 2 packs of Prosure® per day during chemoradiotherapy. Results: A total of 17 patients were included in this study. The reduction in body weight was significantly improved compared with that in the historical control group that did not receive Prosure®(7.3% vs 10.3%, p<0.01), and the rate of Grade 3-4 oral mucositis was significantly reduced for the patient groups that received Prosure®(CTCAE v3.0 Grade≥3; 24% vs 58%, p<0.05). The completion rate of chemoradiotherapy was not significantly different between both groups(77% vs 60%, NS). Conclusions: A nutritional supplement with a high blend ratio of ω-3 fatty acids(Prosure®)had effects on oral mucositis and body weight loss in head and neck cancer patients treated with chemoradiotherapy.
要旨
頭頸部癌に対する化学放射線療法により生じる代表的な副作用には口腔粘膜炎と体重減少があげられる。今回われわれは,中咽頭癌,下咽頭癌症例にてシスプラチンと放射線療法を同時併用する化学放射線療法施行症例において,ω3系脂肪酸高配合栄養機能食品であるプロシュア®の口腔粘膜炎と体重減少に対する有用性の検討を行った。放射線治療開始から終了までの期間プロシュア®を投与し,最大体重減少率,口腔粘膜炎,化学放射線療法完遂率についてプロシュア®の介入を行っていない過去の当科症例を対照群として比較検討を行った。プロシュア®投与群は対照群と比べ体重減少率の改善(7.3% vs 10.3%,p<0.01),口腔粘膜炎の改善を認めた(CTCAE v3.0 Grade 3以上; 24% vs 58%,p<0.05)が,化学放射線療法完遂率は両群の差を認めなかった(77% vs 60%,NS)。プロシュア®の投与が化学放射線療法施行中において,体重減少や口腔粘膜炎の改善に寄与する可能性が示唆された。
目次
Background: Oral mucositis and body weight loss are the most critical conditions known to lead to the discontinuation of chemoradiotherapy for head and neck cancer. We investigated the effect of a nutritional supplement with a high blend ratio of ω-3 fatty acids(Prosure®)on body weight loss, oral mucositis, and the completion rate of chemoradiotherapy in patients with oropharyngeal and hypopharyngeal cancer. Patients and methods: The study group comprised patients with oropharyngeal and hypopharyngeal cancer who were treated with concomitant cisplatin and 70 Gy of radiotherapy. These patients received 2 packs of Prosure® per day during chemoradiotherapy. Results: A total of 17 patients were included in this study. The reduction in body weight was significantly improved compared with that in the historical control group that did not receive Prosure®(7.3% vs 10.3%, p<0.01), and the rate of Grade 3-4 oral mucositis was significantly reduced for the patient groups that received Prosure®(CTCAE v3.0 Grade≥3; 24% vs 58%, p<0.05). The completion rate of chemoradiotherapy was not significantly different between both groups(77% vs 60%, NS). Conclusions: A nutritional supplement with a high blend ratio of ω-3 fatty acids(Prosure®)had effects on oral mucositis and body weight loss in head and neck cancer patients treated with chemoradiotherapy.
要旨
頭頸部癌に対する化学放射線療法により生じる代表的な副作用には口腔粘膜炎と体重減少があげられる。今回われわれは,中咽頭癌,下咽頭癌症例にてシスプラチンと放射線療法を同時併用する化学放射線療法施行症例において,ω3系脂肪酸高配合栄養機能食品であるプロシュア®の口腔粘膜炎と体重減少に対する有用性の検討を行った。放射線治療開始から終了までの期間プロシュア®を投与し,最大体重減少率,口腔粘膜炎,化学放射線療法完遂率についてプロシュア®の介入を行っていない過去の当科症例を対照群として比較検討を行った。プロシュア®投与群は対照群と比べ体重減少率の改善(7.3% vs 10.3%,p<0.01),口腔粘膜炎の改善を認めた(CTCAE v3.0 Grade 3以上; 24% vs 58%,p<0.05)が,化学放射線療法完遂率は両群の差を認めなかった(77% vs 60%,NS)。プロシュア®の投与が化学放射線療法施行中において,体重減少や口腔粘膜炎の改善に寄与する可能性が示唆された。